SB1987 EnrolledLRB103 25792 RLC 57149 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
 
6    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7    Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including
11their isomers, esters, ethers, salts, and salts of isomers,
12esters, and ethers, whenever the existence of such isomers,
13esters, ethers and salts is possible within the specific
14chemical designation:
15        (1) Acetylmethadol;
16        (1.1) Acetyl-alpha-methylfentanyl
17    (N-[1-(1-methyl-2-phenethyl)-
18    4-piperidinyl]-N-phenylacetamide);
19        (2) Allylprodine;
20        (3) Alphacetylmethadol, except
21    levo-alphacetylmethadol (also known as levo-alpha-
22    acetylmethadol, levomethadyl acetate, or LAAM);
23        (4) Alphameprodine;

 

 

SB1987 Enrolled- 2 -LRB103 25792 RLC 57149 b

1        (5) Alphamethadol;
2        (6) Alpha-methylfentanyl
3    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
5    propanilido) piperidine;
6        (6.1) Alpha-methylthiofentanyl
7    (N-[1-methyl-2-(2-thienyl)ethyl-
8    4-piperidinyl]-N-phenylpropanamide);
9        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10        (7.1) PEPAP
11    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12        (8) Benzethidine;
13        (9) Betacetylmethadol;
14        (9.1) Beta-hydroxyfentanyl
15    (N-[1-(2-hydroxy-2-phenethyl)-
16    4-piperidinyl]-N-phenylpropanamide);
17        (10) Betameprodine;
18        (11) Betamethadol;
19        (12) Betaprodine;
20        (13) Clonitazene;
21        (14) Dextromoramide;
22        (15) Diampromide;
23        (16) Diethylthiambutene;
24        (17) Difenoxin;
25        (18) Dimenoxadol;
26        (19) Dimepheptanol;

 

 

SB1987 Enrolled- 3 -LRB103 25792 RLC 57149 b

1        (20) Dimethylthiambutene;
2        (21) Dioxaphetylbutyrate;
3        (22) Dipipanone;
4        (23) Ethylmethylthiambutene;
5        (24) Etonitazene;
6        (25) Etoxeridine;
7        (26) Furethidine;
8        (27) Hydroxpethidine;
9        (28) Ketobemidone;
10        (29) Levomoramide;
11        (30) Levophenacylmorphan;
12        (31) 3-Methylfentanyl
13    (N-[3-methyl-1-(2-phenylethyl)-
14    4-piperidyl]-N-phenylpropanamide);
15        (31.1) 3-Methylthiofentanyl
16    (N-[(3-methyl-1-(2-thienyl)ethyl-
17    4-piperidinyl]-N-phenylpropanamide);
18        (32) Morpheridine;
19        (33) Noracymethadol;
20        (34) Norlevorphanol;
21        (35) Normethadone;
22        (36) Norpipanone;
23        (36.1) Para-fluorofentanyl
24    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25    4-piperidinyl]propanamide);
26        (37) Phenadoxone;

 

 

SB1987 Enrolled- 4 -LRB103 25792 RLC 57149 b

1        (38) Phenampromide;
2        (39) Phenomorphan;
3        (40) Phenoperidine;
4        (41) Piritramide;
5        (42) Proheptazine;
6        (43) Properidine;
7        (44) Propiram;
8        (45) Racemoramide;
9        (45.1) Thiofentanyl
10    (N-phenyl-N-[1-(2-thienyl)ethyl-
11    4-piperidinyl]-propanamide);
12        (46) Tilidine;
13        (47) Trimeperidine;
14        (48) Beta-hydroxy-3-methylfentanyl (other name:
15    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16    N-phenylpropanamide);
17        (49) Furanyl fentanyl (FU-F);
18        (50) Butyryl fentanyl;
19        (51) Valeryl fentanyl;
20        (52) Acetyl fentanyl;
21        (53) Beta-hydroxy-thiofentanyl;
22        (54) 3,4-dichloro-N-[2-
23    (dimethylamino)cyclohexyl]-N-
24    methylbenzamide (U-47700); 
25        (55) 4-chloro-N-[1-[2-
26    (4-nitrophenyl)ethyl]-2-piperidinylidene]-

 

 

SB1987 Enrolled- 5 -LRB103 25792 RLC 57149 b

1    benzenesulfonamide (W-18); 
2        (56) 4-chloro-N-[1-(2-phenylethyl)
3    -2-piperidinylidene]-benzenesulfonamide (W-15); 
4        (57) acrylfentanyl (acryloylfentanyl). 
5    (c) Unless specifically excepted or unless listed in
6another schedule, any of the following opium derivatives, its
7salts, isomers and salts of isomers, whenever the existence of
8such salts, isomers and salts of isomers is possible within
9the specific chemical designation:
10        (1) Acetorphine;
11        (2) Acetyldihydrocodeine;
12        (3) Benzylmorphine;
13        (4) Codeine methylbromide;
14        (5) Codeine-N-Oxide;
15        (6) Cyprenorphine;
16        (7) Desomorphine;
17        (8) Diacetyldihydromorphine (Dihydroheroin);
18        (9) Dihydromorphine;
19        (10) Drotebanol;
20        (11) Etorphine (except hydrochloride salt);
21        (12) Heroin;
22        (13) Hydromorphinol;
23        (14) Methyldesorphine;
24        (15) Methyldihydromorphine;
25        (16) Morphine methylbromide;
26        (17) Morphine methylsulfonate;

 

 

SB1987 Enrolled- 6 -LRB103 25792 RLC 57149 b

1        (18) Morphine-N-Oxide;
2        (19) Myrophine;
3        (20) Nicocodeine;
4        (21) Nicomorphine;
5        (22) Normorphine;
6        (23) Pholcodine;
7        (24) Thebacon.
8    (d) Unless specifically excepted or unless listed in
9another schedule, any material, compound, mixture, or
10preparation which contains any quantity of the following
11hallucinogenic substances, or which contains any of its salts,
12isomers and salts of isomers, whenever the existence of such
13salts, isomers, and salts of isomers is possible within the
14specific chemical designation (for the purposes of this
15paragraph only, the term "isomer" includes the optical,
16position and geometric isomers):
17        (1) 3,4-methylenedioxyamphetamine
18    (alpha-methyl,3,4-methylenedioxyphenethylamine,
19    methylenedioxyamphetamine, MDA);
20        (1.1) Alpha-ethyltryptamine
21    (some trade or other names: etryptamine;
22    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
23    3-(2-aminobutyl)indole; a-ET; and AET);
24        (2) 3,4-methylenedioxymethamphetamine (MDMA);
25        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
26    (also known as: N-ethyl-alpha-methyl-

 

 

SB1987 Enrolled- 7 -LRB103 25792 RLC 57149 b

1    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
2    and MDEA);
3        (2.2) N-Benzylpiperazine (BZP);
4        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
5        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
6        (4) 3,4,5-trimethoxyamphetamine (TMA);
7        (5) (Blank);
8        (6) Diethyltryptamine (DET);
9        (7) Dimethyltryptamine (DMT);
10        (7.1) 5-Methoxy-diallyltryptamine;
11        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
12        (9) Ibogaine  (some trade and other names:
13    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
14    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
15    indole; Tabernanthe iboga);
16        (10) Lysergic acid diethylamide;
17        (10.1) Salvinorin A;
18        (10.5) Salvia divinorum (meaning all parts of the
19    plant presently classified botanically as Salvia
20    divinorum, whether growing or not, the seeds thereof, any
21    extract from any part of that plant, and every compound,
22    manufacture, salts, isomers, and salts of isomers whenever
23    the existence of such salts, isomers, and salts of isomers
24    is possible within the specific chemical designation,
25    derivative, mixture, or preparation of that plant, its
26    seeds or extracts);

 

 

SB1987 Enrolled- 8 -LRB103 25792 RLC 57149 b

1        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
2        (12) Peyote (meaning all parts of the plant presently
3    classified botanically as Lophophora williamsii Lemaire,
4    whether growing or not, the seeds thereof, any extract
5    from any part of that plant, and every compound,
6    manufacture, salts, derivative, mixture, or preparation of
7    that plant, its seeds or extracts);
8        (13) N-ethyl-3-piperidyl benzilate (JB 318);
9        (14) N-methyl-3-piperidyl benzilate;
10        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
11    (also known as N-hydroxy-alpha-methyl-
12    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
13        (15) Parahexyl; some trade or other names:
14    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
15    dibenzo (b,d) pyran; Synhexyl;
16        (16) Psilocybin;
17        (17) Psilocyn;
18        (18) Alpha-methyltryptamine (AMT);
19        (19) 2,5-dimethoxyamphetamine
20    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
21        (20) 4-bromo-2,5-dimethoxyamphetamine
22    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
23    4-bromo-2,5-DMA);
24        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
25    Some trade or other names: 2-(4-bromo-
26    2,5-dimethoxyphenyl)-1-aminoethane;

 

 

SB1987 Enrolled- 9 -LRB103 25792 RLC 57149 b

1    alpha-desmethyl DOB, 2CB, Nexus;
2        (21) 4-methoxyamphetamine
3    (4-methoxy-alpha-methylphenethylamine;
4    paramethoxyamphetamine; PMA);
5        (22) (Blank);
6        (23) Ethylamine analog of phencyclidine.
7    Some trade or other names:
8    N-ethyl-1-phenylcyclohexylamine,
9    (1-phenylcyclohexyl) ethylamine,
10    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
11        (24) Pyrrolidine analog of phencyclidine. Some trade
12    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
13    PHP;
14        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
15        (26) 2,5-dimethoxy-4-ethylamphetamine
16    (another name: DOET);
17        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
18    (another name: TCPy);
19        (28) (Blank);
20        (29) Thiophene analog of phencyclidine (some trade
21    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
22    2-thienyl analog of phencyclidine; TPCP; TCP);
23        (29.1) Benzothiophene analog of phencyclidine. Some
24    trade or other names: BTCP or benocyclidine;
25        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
26        (30) Bufotenine (some trade or other names:

 

 

SB1987 Enrolled- 10 -LRB103 25792 RLC 57149 b

1    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
2    3-(2-dimethylaminoethyl)-5-indolol;
3    5-hydroxy-N,N-dimethyltryptamine;
4    N,N-dimethylserotonin; mappine);
5        (31) (Blank);  
6        (32) (Blank);  
7        (33) (Blank);  
8        (34) (Blank); 
9        (34.5) (Blank);  
10        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
11    (2-methyloctan-2-yl)-6a,7, 
12    10,10a-tetrahydrobenzo[c]chromen-1-ol
13    Some trade or other names: HU-210; 
14        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
15    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
16    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
17    salts, and salts of isomers; Some trade or other  
18    names: HU-210, Dexanabinol; 
19        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
20    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
21    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
22    Some trade or other names: HU-211;
23        (37) (Blank);
24        (38) (Blank);
25        (39) (Blank);
26        (40) (Blank);

 

 

SB1987 Enrolled- 11 -LRB103 25792 RLC 57149 b

1        (41) (Blank);
2        (42) Any compound structurally derived from
3    3-(1-naphthoyl)indole or
4    1H-indol-3-yl-(1-naphthyl)methane by substitution at the
5    nitrogen atom of the indole ring by alkyl, haloalkyl,
6    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl whether or not further substituted
9    in the indole ring to any extent, whether or not
10    substituted in the naphthyl ring to any extent. Examples
11    of this structural class include, but are not limited to,
12    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
13        (43) Any compound structurally derived from
14    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
15    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17    halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    in the pyrrole ring to any extent, whether or not
20    substituted in the naphthyl ring to any extent. Examples
21    of this structural class include, but are not limited to,
22    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
23        (44) Any compound structurally derived from
24    1-(1-naphthylmethyl)indene by substitution at the
25    3-position of the indene ring by alkyl, haloalkyl,
26    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

 

 

SB1987 Enrolled- 12 -LRB103 25792 RLC 57149 b

1    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2    2-(4-morpholinyl)ethyl whether or not further substituted
3    in the indene ring to any extent, whether or not
4    substituted in the naphthyl ring to any extent. Examples
5    of this structural class include, but are not limited to,
6    JWH-176;
7        (45) Any compound structurally derived from
8    3-phenylacetylindole by substitution at the nitrogen atom
9    of the indole ring with alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not further substituted
13    in the indole ring to any extent, whether or not
14    substituted in the phenyl ring to any extent. Examples of
15    this structural class include, but are not limited to,
16    JWH-167, JWH-250, JWH-251, and RCS-8;
17        (46) Any compound structurally derived from
18    2-(3-hydroxycyclohexyl)phenol by substitution at the
19    5-position of the phenolic ring by alkyl, haloalkyl,
20    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
21    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl, whether or not substituted in the
23    cyclohexyl ring to any extent. Examples of this structural
24    class include, but are not limited to, CP 47, 497 and its
25    C8 homologue (cannabicyclohexanol);
26        (46.1) Any compound structurally derived from

 

 

SB1987 Enrolled- 13 -LRB103 25792 RLC 57149 b

1    3-(benzoyl) indole with substitution at the nitrogen atom
2    of the indole ring by an alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl group whether or not further
6    substituted in the indole ring to any extent and whether
7    or not substituted in the phenyl ring to any extent.
8    Examples of this structural class include, but are not
9    limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
10    48,098), and RCS-4;
11        (47) (Blank);
12        (48) (Blank);
13        (49) (Blank);
14        (50) (Blank);
15        (51) (Blank);
16        (52) (Blank);
17        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
18    Some trade or other names: 2C-T-7;
19        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
20    trade or other names: 2C-E;
21        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
22    trade or other names: 2C-D;
23        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
24    trade or other names: 2C-C;
25        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
26    or other names: 2C-I;

 

 

SB1987 Enrolled- 14 -LRB103 25792 RLC 57149 b

1        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
2    trade or other names: 2C-T-2;
3        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
4    Some trade or other names: 2C-T-4;
5        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
6    other names: 2C-H;
7        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
8    trade or other names: 2C-N;
9        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
10    trade or other names: 2C-P;
11        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
12    Some trade or other names: 2C-G;
13        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
14    phenethylamine referred to in subparagraphs (20.1), (53),
15    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
16    (53.8), (53.9), and (53.10) including, but not limited to,
17    25I-NBOMe and 25C-NBOMe;
18        (54) 5-Methoxy-N,N-diisopropyltryptamine;
19        (55) (Blank);
20        (56) (Blank);
21        (57) (Blank);
22        (58) (Blank);
23        (59) 3-cyclopropoylindole with substitution at the
24    nitrogen atom of the indole ring by alkyl, haloalkyl,
25    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB1987 Enrolled- 15 -LRB103 25792 RLC 57149 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indole ring to any extent, whether or not
3    substituted on the cyclopropyl ring to any extent:
4    including, but not limited to, XLR11, UR144, FUB-144;
5        (60) 3-adamantoylindole with substitution at the
6    nitrogen atom of the indole ring by alkyl, haloalkyl,
7    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indole ring to any extent, whether or not
11    substituted on the adamantyl ring to any extent:
12    including, but not limited to, AB-001;
13        (61) N-(adamantyl)-indole-3-carboxamide with
14    substitution at the nitrogen atom of the indole ring by
15    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16    cycloalkylethyl, aryl halide, alkyl aryl halide,
17    1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indole ring to any extent, whether or not
20    substituted on the adamantyl ring to any extent:
21    including, but not limited to, APICA/2NE-1, STS-135;
22        (62) N-(adamantyl)-indazole-3-carboxamide with
23    substitution at a nitrogen atom of the indazole ring by
24    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25    cycloalkylethyl, aryl halide, alkyl aryl halide,
26    1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB1987 Enrolled- 16 -LRB103 25792 RLC 57149 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indazole ring to any extent, whether or not
3    substituted on the adamantyl ring to any extent:
4    including, but not limited to, AKB48, 5F-AKB48;
5        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
6    with substitution at the nitrogen atom of the indole ring
7    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8    cycloalkylethyl, aryl halide, alkyl aryl halide,
9    1-(N-methyl-2-piperidinyl)methyl, or
10    2-(4-morpholinyl)ethyl, whether or not further substituted
11    on the indole ring to any extent, whether or not
12    substituted on the quinoline ring to any extent:
13    including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
14        (64) 3-(1-naphthoyl)indazole with substitution at the
15    nitrogen atom of the indazole ring by alkyl, haloalkyl,
16    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
17    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indazole ring to any extent, whether or not
20    substituted on the naphthyl ring to any extent: including,
21    but not limited to, THJ-018, THJ-2201;
22        (65) 2-(1-naphthoyl)benzimidazole with substitution
23    at the nitrogen atom of the benzimidazole ring by alkyl,
24    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25    aryl halide, alkyl aryl halide,
26    1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB1987 Enrolled- 17 -LRB103 25792 RLC 57149 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the benzimidazole ring to any extent, whether or not
3    substituted on the naphthyl ring to any extent: including,
4    but not limited to, FUBIMINA;
5        (66)
6    N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
7    3-carboxamide with substitution on the nitrogen atom of
8    the indazole ring by alkyl, haloalkyl, alkenyl,
9    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10    halide, 1-(N-methyl-2-piperidinyl)methyl, or
11    2-(4-morpholinyl)ethyl, whether or not further substituted
12    on the indazole ring to any extent: including, but not
13    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
14        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
15    indazole-3-carboxamide with substitution on the nitrogen
16    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18    halide, 1-(N-methyl-2-piperidinyl)methyl, or
19    2-(4-morpholinyl)ethyl, whether or not further substituted
20    on the indazole ring to any extent: including, but not
21    limited to, ADB-PINACA, ADB-FUBINACA;
22        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
23    indole-3-carboxamide with substitution on the nitrogen
24    atom of the indole ring by alkyl, haloalkyl, alkenyl,
25    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26    halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB1987 Enrolled- 18 -LRB103 25792 RLC 57149 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indole ring to any extent: including, but not
3    limited to, ADBICA, 5F-ADBICA;
4        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
5    3-carboxamide with substitution on the nitrogen atom of
6    the indole ring by alkyl, haloalkyl, alkenyl,
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8    halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indole ring to any extent: including, but not
11    limited to, ABICA, 5F-ABICA;
12        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
13    methylbutanoate with substitution on the nitrogen atom of
14    the indazole ring by alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16    halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indazole ring to any extent: including, but not
19    limited to, AMB, 5F-AMB;
20        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
21    dimethylbutanoate with substitution on the nitrogen atom
22    of the indazole ring by alkyl, haloalkyl, alkenyl,
23    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24    halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indazole ring to any extent: including, but not

 

 

SB1987 Enrolled- 19 -LRB103 25792 RLC 57149 b

1    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
2        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
3    methylbutanoate with substitution on the nitrogen atom of
4    the indole ring by alkyl, haloalkyl, alkenyl,
5    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6    halide, 1-(N-methyl-2-piperidinyl)methyl, or
7    2-(4-morpholinyl)ethyl, whether or not further substituted
8    on the indazole ring to any extent: including, but not
9    limited to, MMB018, MMB2201, and AMB-CHMICA;
10        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
11    dimethylbutanoate with substitution on the nitrogen atom
12    of the indole ring by alkyl, haloalkyl, alkenyl,
13    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14    halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indazole ring to any extent: including, but not
17    limited to, MDMB-CHMICA;
18        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
19    indazole-3-carboxamide with substitution on the nitrogen
20    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22    halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indazole ring to any     extent: including, but not
25    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
26        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-

 

 

SB1987 Enrolled- 20 -LRB103 25792 RLC 57149 b

1    3-carboxamide with substitution on the nitrogen atom of
2    the indole ring by alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl, whether or not further substituted
6    on the indazole ring to any extent: including, but not
7    limited to, APP-PICA and 5-fluoro-APP-PICA;
8        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
9    4-AcO-DMT;
10        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
11    name 5-MeO-MIPT;
12        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
13        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
14        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
15        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
16    (4-HO-MiPT);
17        (82) Fluorophenylpiperazine;
18        (83) Methoxetamine;
19        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
20    ethcathinone).
21    (e) Unless specifically excepted or unless listed in
22another schedule, any material, compound, mixture, or
23preparation which contains any quantity of the following
24substances having a depressant effect on the central nervous
25system, including its salts, isomers, and salts of isomers
26whenever the existence of such salts, isomers, and salts of

 

 

SB1987 Enrolled- 21 -LRB103 25792 RLC 57149 b

1isomers is possible within the specific chemical designation:
2        (1) mecloqualone;
3        (2) methaqualone; and
4        (3) gamma hydroxybutyric acid.
5    (f) Unless specifically excepted or unless listed in
6another schedule, any material, compound, mixture, or
7preparation which contains any quantity of the following
8substances having a stimulant effect on the central nervous
9system, including its salts, isomers, and salts of isomers:
10        (1) Fenethylline;
11        (2) N-ethylamphetamine;
12        (3) Aminorex (some other names:
13    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
14    4-5-dihydro-5-phenyl-2-oxazolamine) and its
15    salts, optical isomers, and salts of optical isomers;
16        (4) Methcathinone (some other names:
17    2-methylamino-1-phenylpropan-1-one;
18    Ephedrone; 2-(methylamino)-propiophenone;
19    alpha-(methylamino)propiophenone; N-methylcathinone;
20    methycathinone; Monomethylpropion; UR 1431) and its
21    salts, optical isomers, and salts of optical isomers;
22        (5) Cathinone (some trade or other names:
23    2-aminopropiophenone; alpha-aminopropiophenone;
24    2-amino-1-phenyl-propanone; norephedrone);
25        (6) N,N-dimethylamphetamine (also known as:
26    N,N-alpha-trimethyl-benzeneethanamine;

 

 

SB1987 Enrolled- 22 -LRB103 25792 RLC 57149 b

1    N,N-alpha-trimethylphenethylamine);
2        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
3    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
4        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
5        (9) Halogenated amphetamines and
6    methamphetamines - any compound derived from either
7    amphetamine or methamphetamine through the substitution
8    of a halogen on the phenyl ring, including, but not
9    limited to, 2-fluoroamphetamine, 3-
10    fluoroamphetamine and 4-fluoroamphetamine; 
11        (10) Aminopropylbenzofuran (APB):
12    including 4-(2-Aminopropyl) benzofuran, 5-
13    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
14    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
15        (11) Aminopropyldihydrobenzofuran (APDB):
16    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
17    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
18    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
19    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
20        (12) Methylaminopropylbenzofuran
21    (MAPB): including 4-(2-methylaminopropyl)
22    benzofuran, 5-(2-methylaminopropyl)benzofuran,
23    6-(2-methylaminopropyl)benzofuran
24    and 7-(2-methylaminopropyl)benzofuran. 
25    (g) Temporary listing of substances subject to emergency
26scheduling. Any material, compound, mixture, or preparation

 

 

SB1987 Enrolled- 23 -LRB103 25792 RLC 57149 b

1that contains any quantity of the following substances:
2        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
3    (benzylfentanyl), its optical isomers, isomers, salts, and
4    salts of isomers;
5        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
6    phenylpropanamide (thenylfentanyl), its optical isomers,
7    salts, and salts of isomers.
8    (h) Synthetic cathinones. Unless specifically excepted,
9any chemical compound which is not approved by the United
10States Food and Drug Administration or, if approved, is not
11dispensed or possessed in accordance with State or federal
12law, not including bupropion, structurally derived from
132-aminopropan-1-one by substitution at the 1-position with
14either phenyl, naphthyl, or thiophene ring systems, whether or
15not the compound is further modified in one or more of the
16following ways:
17        (1) by substitution in the ring system to any extent
18    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
19    halide substituents, whether or not further substituted in
20    the ring system by one or more other univalent
21    substituents. Examples of this class include, but are not
22    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
23        (2) by substitution at the 3-position with an acyclic
24    alkyl substituent. Examples of this class include, but are
25    not limited to, 2-methylamino-1-phenylbutan-1-one
26    (buphedrone); or

 

 

SB1987 Enrolled- 24 -LRB103 25792 RLC 57149 b

1        (3) by substitution at the 2-amino nitrogen atom with
2    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
3    inclusion of the 2-amino nitrogen atom in a cyclic
4    structure. Examples of this class include, but are not
5    limited to, Dimethylcathinone, Ethcathinone, and
6    a-Pyrrolidinopropiophenone (a-PPP); or
7    Any other synthetic cathinone which is not approved by the
8United States Food and Drug Administration or, if approved, is
9not dispensed or possessed in accordance with State or federal
10law.
11    (i) Synthetic cannabinoids or piperazines. Any synthetic
12cannabinoid or piperazine which is not approved by the United
13States Food and Drug Administration or, if approved, which is
14not dispensed or possessed in accordance with State and
15federal law.
16    (j) Unless specifically excepted or listed in another
17schedule, any chemical compound which is not approved by the
18United States Food and Drug Administration or, if approved, is
19not dispensed or possessed in accordance with State or federal
20law, and is derived from the following structural classes and
21their salts:
22        (1) Benzodiazepine class: A fused 1,4-diazepine and
23    benzene ring structure with a phenyl connected to the
24    1,4-diazepine ring, with any substitution(s) or
25    replacement(s) on the 1,4-diazepine or benzene ring, any
26    substitution(s) on the phenyl ring, or any combination

 

 

SB1987 Enrolled- 25 -LRB103 25792 RLC 57149 b

1    thereof. Examples of this class include but are not
2    limited to: Clonazolam, Flualprazolam; or
3        (2) Thienodiazepine class: A fused 1,4-diazepine and
4    thiophene ring structure with a phenyl connected to the
5    1,4-diazepine ring, with any substitution(s) or
6    replacement(s) on the 1,4-diazepine or thiophene ring, any
7    substitution(s) on the phenyl ring, or any combination
8    thereof. Examples of this class include but are not
9    limited to: Etizolam.
10(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
11100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
128-14-18.)